The Barrier of Hypoglycemia in Diabetes
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Glycemic control, a worthwhile goal for people with diabetes, is limited by the barrier of iatrogenic hypoglycemia (1). Iatrogenic hypoglycemia 1 ) causes recurrent morbidity in most people with type 1 diabetes and many with advanced type 2 diabetes and is sometimes fatal, 2 ) compromises physiological and behavioral defenses against subsequent falling plasma glucose concentrations and thus causes a vicious cycle of recurrent hypoglycemia, and 3 ) precludes maintenance of euglycemia over a lifetime of diabetes and therefore full realization of the vascular benefits of glycemic control. The premise of this “Perspective in Diabetes” is that insight into the pathophysiology of glucose counterregulation in diabetes leads to understanding of the frequency and impact of, risk factors for, and prevention of iatrogenic hypoglycemia. Partial glycemic control reduces, but does not eliminate, the development of microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy) in type 1 (2) and type 2 (3,4) diabetes. Extrapolation of the Diabetes Control and Complications Trial (DCCT) retinopathy data suggests that long-term maintenance of euglycemia might eliminate those complications (5). Follow-up of the DCCT patients seemingly indicates that a period of earlier partial glycemic control reduces the development of macrovascular complications in type 1 diabetes (6). Aside from the metformin subset of the U.K. Prospective Diabetes Study (4), randomized controlled trials of intensive glycemic therapy have not documented a cardiovascular mortality benefit in type 2 diabetes (3,7,8). However, those trials do not exclude a cardiovascular benefit if glycemic control, or even partial glycemic control, could be maintained over a longer period of time. In any event, given its documented microvascular benefit, maintenance of euglycemia over a lifetime of diabetes would be in the best interest of people with diabetes if that could be accomplished safely. Unfortunately, maintenance of euglycemia over a lifetime of diabetes …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HAAF is a form of functional sympathoadrenal failure that is most often caused by recent antecedent iatrogenic hypoglycemia (25) and is at least partly reversible by scrupulous avoidance of hypoglycemia (32–34).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, because type 2 diabetes is much more prevalent than type 1 diabetes, most episodes of hypoglycemia, including severe hypoglycemia, occur in people with type 2 diabetes (25).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, most episodes of iatrogenic hypoglycaemia, including severe hypoglycaemia, occur in people with type 2 diabetes [15].”
From Preventing hypoglycaemia: what is the appropriate glucose alert value? (2009) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, because type 2 diabetes is much more prevalent than type 1 diabetes, most episodes of hypoglycemia, including severe hypoglycemia, occur in people with type 2 diabetes (25).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that multiple pathways in addition to the adrenergic system could be simultaneously involved in the pathogenesis of HAAF (8, 33, 34).”
From Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure (2020) · cites this paper as [33]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Research works printed but not linked: 1
- Cryer PE: Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention. American Diabetes Association, Alexandria, VA. In press
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
“especially in type 1 diabetes (51) [E].”
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
“However, because type 2 diabetes is much more prevalent than type 1 diabetes, most episodes of hypoglycemia, including severe hypoglycemia, occur in people with type 2 diabetes (25).”
BackgroundSelf-citationHypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Self-citationIncreased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Diabetes Care · doi:10.2337/dci15-0012 · Cited by 492
Home Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4127 · Cited by 412
Self-citationAgiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., Deedwania, P., Eckel, R. H., Ershow, A. G., Fradkin, J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000230 · Cited by 386
Engineering living therapeutics with synthetic biology
Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P. F., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 356
Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346
Bellin, M. D., Barton, F. B., Heitman, A., Harmon, J. V., Kandaswamy, R., Balamurugan, A. N., Sutherland, D. E. R., Alejandro, R., & Hering, B. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03977.x · Cited by 350
Jing, X., Chen, J., Dong, Y., Han, D., Zhao, H., Wang, X., Gao, F., Li, C., Cui, Z., Liu, Y., et al. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-1021-9 · Cited by 336
Glaesner, W., Mark Vick, A., Millican, R., Ellis, B., Tschang, S., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., et al. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1080 · Cited by 305
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299
Leptin revisited: its mechanism of action and potential for treating diabetes
Coppari, R., & Bjørbæk, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3757 · Cited by 293
Hemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T. P., & Wetterslev, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008143.pub4 · Cited by 291
Rosenstock, J., Jelaska, A., Zeller, C., Kim, G., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA‐REG BASAL trial investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12503 · Cited by 252
Hovorka, R., Kumareswaran, K., Harris, J., Allen, J. M., Elleri, D., Xing, D., Kollman, C., Nodale, M., Murphy, H. R., Dunger, D. B., et al. (2011) · BMJ · doi:10.1136/bmj.d1855 · Cited by 244
Choudhary, P., Rickels, M. R., Senior, P. A., Vantyghem, M.-C., Maffi, P., Kay, T. W., Keymeulen, B., Inagaki, N., Saudek, F., Lehmann, R., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0090 · Cited by 233
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
Mechanisms of hypoglycemia unawareness and implications in diabetic patients
Martín-Timón, I. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.912 · Cited by 204
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Self-citationAction and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
(2011) · PubMed · Cited by 187
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177
Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes
Weinstock, R. S., DuBose, S. N., Bergenstal, R. M., Chaytor, N. S., Peterson, C., Olson, B. A., Munshi, M. N., Perrin, A. J. S., Miller, K. M., Beck, R. W., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1426 · Cited by 171
Barnard, K. D., Wysocki, T., Allen, J. M., Elleri, D., Thabit, H., Leelarathna, L., Gulati, A., Nodale, M., Dunger, D. B., Tinati, T., et al. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000025 · Cited by 159
Advancing islet transplantation: from engraftment to the immune response
Gibly, R. F., Graham, J. G., Luo, X., Lowe, W. L., Hering, B. J., & Shea, L. D. (2011) · Diabetologia · doi:10.1007/s00125-011-2243-0 · Cited by 143
Breton, M. D., Brown, S. A., Karvetski, C. H., Kollar, L., Topchyan, K. A., Anderson, S. M., & Kovatchev, B. P. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0333 · Cited by 128
Lee, A. K., Lee, C. J., Huang, E. S., Sharrett, A. R., Coresh, J., & Selvin, E. (2017) · Diabetes Care · doi:10.2337/dc17-0819 · Cited by 119
Goldenberg, R. M., Gilbert, J. D., Hramiak, I. M., Woo, V. C., & Zinman, B. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13811 · Cited by 114
HYPOS-1 Study Group of AMD, Giorda, C. B., Ozzello, A., Gentile, S., Aglialoro, A., Chiambretti, A., Baccetti, F., Gentile, F. M., Lucisano, G., Nicolucci, A., et al. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0713-4 · Cited by 97
Susceptibility of Interstitial Continuous Glucose Monitor Performance to Sleeping Position
Mensh, B. D., Wisniewski, N. A., Neil, B. M., & Burnett, D. R. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700408 · Cited by 97
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96
Ratzki-Leewing, A., Harris, S. B., Mequanint, S., Reichert, S. M., Belle Brown, J., Black, J. E., & Ryan, B. L. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000503 · Cited by 90
Ranjan, A., Schmidt, S., Damm-Frydenberg, C., Steineck, I., Clausen, T. R., Holst, J. J., Madsbad, S., & Nørgaard, K. (2017) · Diabetes Care · doi:10.2337/dc16-1472 · Cited by 89
Insulin Stacking Versus Therapeutic Accumulation: Understanding the Differences
Heise, T., & Meneghini, L. F. (2014) · Endocrine Practice · doi:10.4158/ep13090.ra · Cited by 87
Yashiro, H., Tsujihata, Y., Takeuchi, K., Hazama, M., Johnson, P. R. V., & Rorsman, P. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187708 · Cited by 84
Lin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Preventing hypoglycaemia: what is the appropriate glucose alert value?
Cryer, P. E. (2009) · Diabetologia · doi:10.1007/s00125-008-1205-7 · Cited by 77
Self-citationMcCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2013) · Endocrine Practice · doi:10.4158/ep12382.or · Cited by 76
Yue, J. T. Y., Burdett, E., Coy, D. H., Giacca, A., Efendic, S., & Vranic, M. (2012) · Diabetes · doi:10.2337/db11-0690 · Cited by 75
Reddy, M., Pesl, P., Xenou, M., Toumazou, C., Johnston, D., Georgiou, P., Herrero, P., & Oliver, N. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0413 · Cited by 70
Rickels, M. R. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14214 · Cited by 71
Karimian, N., Qin, T., Liang, T., Osundiji, M., Huang, Y., Teich, T., Riddell, M. C., Cattral, M. S., Coy, D. H., Vranic, M., et al. (2013) · Diabetes · doi:10.2337/db13-0164 · Cited by 66
Burnett, D. R., Huyett, L. M., Zisser, H. C., Doyle, F. J., & Mensh, B. D. (2014) · Diabetes · doi:10.2337/db13-1649 · Cited by 52
Leiter, L. A., Boras, D., & Woo, V. C. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.270 · Cited by 48
Misra-Hebert, A. D., Pantalone, K. M., Ji, X., Milinovich, A., Dey, T., Chagin, K. M., Bauman, J. M., Kattan, M. W., & Zimmerman, R. S. (2018) · Diabetes Care · doi:10.2337/dc17-1834 · Cited by 46
Rondags, S. M. P. A., de Wit, M., Twisk, J. W., & Snoek, F. J. (2016) · Diabetes Care · doi:10.2337/dc16-1614 · Cited by 45
Yue, J. T. Y., Riddell, M. C., Burdett, E., Coy, D. H., Efendic, S., & Vranic, M. (2013) · Diabetes · doi:10.2337/db12-1523 · Cited by 45
Adrenergic mediation of hypoglycemia-associated autonomic failure
Ramanathan, R., & Cryer, P. E. (2011) · Diabetes · doi:10.2337/db10-1374 · Cited by 42
Self-citationHaymond, M. W., DuBose, S. N., Rickels, M. R., Wolpert, H., Shah, V. N., Sherr, J. L., Weinstock, R. S., Agarwal, S., Verdejo, A. S., Cummins, M. J., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00591 · Cited by 42
Hypoglycemia: Minimizing its impact in type 2 diabetes
Moghissi, E., Ismail-Beigi, F., & Devine, R. C. (2013) · Endocrine Practice · doi:10.4158/ep13005.ra · Cited by 39
Experimental hypoglycemia is a human model of stress-induced hyperalgesia
Gibbons, C. H., Adler, G. K., Bonyhay, I., & Freeman, R. (2012) · Pain · doi:10.1016/j.pain.2012.06.030 · Cited by 38
Korsatko, S., Jensen, L., Brunner, M., Sach‐Friedl, S., Tarp, M. D., Holst, A. G., Heller, S. R., & Pieber, T. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13422 · Cited by 29
Seaquist, E. R., Blonde, L., McGill, J. B., Heller, S. R., Kendall, D. M., Bumpass, J. B., Pompilio, F. M., & Grant, M. L. (2020) · Diabetic Medicine · doi:10.1111/dme.14202 · Cited by 30
Opioid receptor activation impairs hypoglycemic Counterregulation in humans
Carey, M., Gospin, R., Goyal, A., Tomuta, N., Sandu, O., Mbanya, A., Lontchi-Yimagou, E., Hulkower, R., Shamoon, H., Gabriely, I., et al. (2017) · Diabetes · doi:10.2337/db16-1478 · Cited by 23
Hirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
Zhang, Z., Lovato, J., Battapady, H., Davatzikos, C., Gerstein, H. C., Ismail-Beigi, F., Launer, L. J., Murray, A., Punthakee, Z., Tirado, A. A., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0973 · Cited by 20
Modeling Glucagon Action in Patients With Type 1 Diabetes
Emami, A., Youssef, J. E., Rabasa-Lhoret, R., Pineau, J., Castle, J. R., & Haidar, A. (2017) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2016.2593630 · Cited by 20
Senthilkumaran, M., Zhou, X.-F., & Bobrovskaya, L. (2016) · International Journal of Endocrinology · doi:10.1155/2016/9801640 · Cited by 19
Stem cells and beta cell replacement therapy: a prospective health technology assessment study
Wallner, K., Pedroza, R. G., Awotwe, I., Piret, J. M., Senior, P. A., Shapiro, A. M. J., & McCabe, C. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0233-7 · Cited by 19
Pharmacokinetics Modeling of Exogenous Glucagon in Type 1 Diabetes Mellitus Patients
Lv, D., Breton, M. D., & Farhy, L. S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0150 · Cited by 17
Lontchi-Yimagou, E., Aleksic, S., Hulkower, R., Gospin, R., Goyal, A., Kuo, B., Mitchell, W. G., You, J. Y., Upadhyay, L., Carey, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa539 · Cited by 17
Zaccardi, F., Webb, D. R., Davies, M. J., Dhalwani, N. N., Housley, G., Shaw, D., Hatton, J. W., & Khunti, K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12941 · Cited by 15
Dalal, M. R., Kazemi, M. R., & Ye, F. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1248911 · Cited by 14
Farhat, R., Su, G., Sejling, A.-S., Knight, N., Fisher, S. J., & Chan, O. (2019) · Diabetologia · doi:10.1007/s00125-018-4802-0 · Cited by 12
Tidemand, K. G., Laugesen, C., Ranjan, A. G., Skovhus, L. B., & Nørgaard, K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0134 · Cited by 9
Metadata
- Authors
- Cryer, P. E.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, Philip E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-12-01
- Volume
- 57
- Issue
- 12
- Pages
- 3169-3176
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2584119
- OpenAlex
- W2014554878
- Cited by
- 725
- References
- 51
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 35 · 2023: 31 · 2022: 33 · 2021: 47 · 2020: 34 · 2019: 48 · 2018: 38 · 2017: 38 · 2016: 53 · 2015: 66 · 2014: 49 · 2013: 56 · 2012: 43
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- National Institutes of Health (5p60dk020579-35, UL1TR000448, DK20579, P60-DK-20579, RR‐00036)
- U.S. Public Health Service
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, P60-DK-020579, T32DK007120)
- National Center for Research Resources (MO1RR00036, UL1RR024992, M01RR000036)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- iatrogenic hypoglycemia, glycemic control, glucose counterregulation, type 1 diabetes, type 2 diabetes, normoglycemia, hypoglycemia prevention, hypoglycemia risk factors, microvascular complications, macrovascular complications
- MeSH terms
- Blood Glucose, Brain, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Coma, Female, Homeostasis, Humans, Hypoglycemia, Male, Risk Factors, Risk Reduction Behavior, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.